Role of necroptosis in the pathogenesis of solid organ injury

H Zhao, T Jaffer, S Eguchi, Z Wang, A Linkermann and D Ma

Necroptosis is a type of regulated cell death dependent on the activity of receptor-interacting serine/threonine-protein (RIP) kinases. However, unlike apoptosis, it is caspase independent. Increasing evidence has implicated necroptosis in the pathogenesis of disease, including ischemic injury, neurodegeneration, viral infection and many others. Key players of the necroptosis signalling pathway are now widely recognized as therapeutic targets. Necrostatins may be developed as potent inhibitors of necroptosis, targeting the activity of RIPK1. Necrostatin-1, the first generation of necrostatins, has been shown to confer potent protective effects in different animal models. This review will summarize novel insights into the involvement of necroptosis in specific injury of different organs, and the therapeutic platform that it provides for treatment.

Cell Death and Disease (2015) 6, e1975; doi:10.1038/cddis.2015.316; published online 19 November 2015

Facts

• Necroptosis is a type of regulated cell death dependent on the activity of receptor-interacting serine/threonine-protein (RIP) kinases
• Necroptosis induces inflammation through the release of Danger-associated molecular patterns (DAMPs), such as HMGB-1.
• Necroptosis is closely associated with acute injury in brain, heart, lung, kidney, liver, intestine and pancreas.

Open Questions

• What is the exact molecular mechanism of necroptosis in solid organ injury?
• How is necroptosis related to diagnosis and prognosis of the solid organ injury?
• Which therapeutic strategy would be the most effective against necroptosis-associated solid organ injury in clinical settings?

Apoptosis and necrosis are two pathologically relevant types of cell death. Apoptosis is programmed cell death controlled tightly during development and in physiological cellular turnover; necrosis, which also occurs in trauma, was thought to occur predominantly in an uncontrolled manner.1 Necroptosis involves the loss of membrane integrity, release of damage-associated molecular pattern molecules (DAMPs) and is therefore closely associated with inflammatory response.2 It involves the activation of specific death mediators such as receptor-interacting protein (RIP) kinases and mixed-lineage kinase domain-like protein (MLKL).3,4 Recent studies implicate that necroptosis is of central relevance in different disease states, such as myocardial infarction,5 stroke6 and organ graft ischemia–reperfusion injury (IRI).7-9 This review will summarize new insights into the molecular mechanisms of necroptosis in different pathological conditions and provide an overview of the currently available therapeutic approaches, which target necroptosis in organ injury.

Molecular Mechanism of Necroptosis

The molecular pathway of tumor necrosis factor alpha (TNF-α)-induced necroptosis is the mostly intensively investigated (Figure 1). TNF-α-induced necroptosis involves two members of the receptor-interacting protein (RIP) family of kinases – RIPK1 and RIPK3.3,10 Tumor necrosis factor-α (TNF-α) can bind to one of two receptors, TNFR1 or TNFR2. TNFR activation can cause the activation of NF-κB which leads to the induction of proinflammatory cytokines.11 However, the activation of TNFR1 may turn into a death signal, which recruits several proteins.12 Upon TNF stimulation, TNFR1 complex I is formed at the plasma membrane, containing cellular inhibitor of apoptosis protein 1 (cIAP-1) and transforming growth factor-β-activated kinase 1 (TAK1).13

1Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK and 2Division of Nephrology and Hypertension, Christian-Albrechts-University, Kiel, Germany
*Corresponding author: D Ma, Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. Tel: +44 020 3315 8495; Fax: +44 020 3315 5109; E-mail: d.ma@imperial.ac.uk

Abbreviations: TNF, tumor necrosis factor; TRADD, TNFRSF1A-associated via death domain; TRAF, TNF receptor associated factors; cIAPs, cellular inhibitor of apoptosis protein; CYLD, deubiquitinase cylindromatosis; MLKL, mediator mixed-lineage kinase domain like; RIP, receptor-interacting protein kinase; Drp1, dynamin-related protein 1; TAK1, transforming growth factor-β-activated kinase 1; HMGB-1, high-mobility group protein B1; HSP, heat shock protein; DAMP, damage-associated molecular patterns; RAGE, advanced glycation end products; TLR, Toll-like receptors; AKI, acute kidney injury

Received 09.7.15; revised 16.9.15; accepted 18.9.15; Edited by E Baehrecke
The transition from TNFR1 complex I to the cytosolic death-inducing TNFR1 complex II requires the activity of cylindromatosis (CYLD), a deubiquitylating enzyme. More recent data suggest that CYLD likely regulates activation of RIPK1 in Complex II, rather than transition from Complex I to Complex II. Within TNFR1 complex II, the apoptotic machinery FADD, c-FLIP and caspase-8 suppresses the induction of necroptosis. Caspase-8 inactivates RIPK1 and RIPK3 by proteolytic cleavage and the proapoptotic caspase activation is initiated. Mechanistic data indicate that CYLD is essential for necrosis and serves as a target for proteolysis by caspase-8. When caspase-8 is inactivated or absent, RIPK1 and RIPK3 are not cleaved and become phosphorylated. They then form a necosome and the cell undergoes necroptosis. RIPK1 then recruits RIPK3 through RIP (RHIM) domain-mediated interactions. This RIPK1–RIPK3 interaction promotes the recruitment and phosphorylation of mixed-lineage kinase domain-like (MLKL) protein. Phosphorylated MLKL forms tetramers and translocates onto the plasma membrane, and in turn initiates Ca \(^{2+}\) influx. In addition, RIPK3 is reported to activate a number of different downstream signals such as phosphoglycerate mutase 5 and finally dynamin-related protein (Drp1) to induce reactive oxygen species (ROS) production in the mitochondria and mediate plasma membrane rupture. Abbreviation: TNF, tumor necrosis factor; TRADD, TNFRSF1A-associated via death domain; TRAF, TNF receptor associated factors; cIAPs, cellular inhibitor of apoptosis protein; CYLD, deubiquitinase cylindromatosis; MLKL, mediator mixed-lineage kinase domain like; RIP, receptor-interacting protein kinase; PGAM5, phosphoglycerate mutase 5; Drp1, dynamin-related protein 1.
of TNFR1, RIPK1 or MLKL shifted endoplasmic reticulum stress induced necroptosis to apoptosis. Necroptosis is caspase independent and is not inhibited by caspase inhibitors, such as zVAD fluoromethyl ketone. Necroptosis can be inhibited by Necrostatin-1 through suppression of RIPK1 activity. The difference between apoptosis, necrosis and necroptosis is summarized in Table 1. RIPK1 has been shown to be involved in RIPK3/MLKL-dependent necrototic cell death. However, RIPK1 was found to drive NF-κB-mediated cell survival and inflammation through activating downstream of either TNFR1 or TNFR2 as well as caspase-8-dependent apoptotic cell death. Depletion of RIPK1 has been shown to lead to enhanced sensitization to TNF-induced apoptosis and pharmacological inhibition of RIPK1 activities is associated with suppression of necroptosis. Recent data clearly indicate that RIPK1 serves a critical kinase-independent scaffolding role and prevents inappropriate activation of both RIPK3-dependent necroptosis and caspase-8-dependent apoptosis.

### Necroptosis in Organ Injury

Accumulating laboratory studies demonstrate that acute or chronic organ injury can lead to necroptosis. To date, necroptosis has been found to be present as a result of certain disease or injury in major organs of the body (Figure 3). Understanding of necroptosis in the pathophysiology of various diseases may offer unique opportunities for clinical management of such patients.

### Brain

**Neonatal hypoxia–ischemia brain injury:** Necroptosis has been recognized as an important mechanism of injury in neonatal hypoxia–ischemia (HI) brain injury. In the mouse model of neonatal HI, necrostatin-1 blocked the interaction of RIPK1 and RIPK3 in the neurons. Cytokine gene and protein expression, such as interleukin IL-1β, IL-6 and TNFα, was suppressed, and NF-κB activation was inhibited. This study showed that Necrostatin-1 could be protective against neonatal brain injury after HI through attenuation of necroptosis-associated neuro-inflammation.

**Traumatic brain injury:** Necroptosis has been shown to play a critical role in the pathogenesis of cell death during traumatic brain injury (TBI). Mice administered with Necrostatin-1 had reduced brain damage and improved motor and cognitive performance after TBI. Necrostatin-1 has been demonstrated to decrease brain neutrophil infiltration and suppress microglial activation. These data therefore suggest that Necrostatin-1 may offer a new therapeutic perspective for treatment of patients with TBI.

**Ischemic stroke:** The pathological relevance of necroptosis in an ischemic stroke setting was established in a study by Degterev et al. In a mouse model of transient focal cerebral ischemia, it was shown that necroptosis contributed to delayed ischemic brain injury. In addition, intracerebroventricular administration of Necrostatin-1 markedly decreased the infarct volume, indicating a therapeutic potential for stroke.

### Table 1 Difference between apoptosis, necrosis and necroptosis

| Type of cell death | Apoptosis | Necrosis | Necroptosis |
|-------------------|-----------|----------|-------------|
| Trigger           | Controlled| Uncontrolled| Controlled  |
| Morphology        | Extensive membrane blebbing, condensation and fragmentation of the nucleus | Extensive organelle and cell swelling, loss of membrane integrity, release of extracellular contents | Cytoplasmic swelling, rupture of the plasma membrane and spilling of the intracellular content |
| Signalling pathway| Specific, intrinsic or extrinsic pathways | Unspecific | Specific, e.g TNFR1 pathway |
| Executioner       | Caspase, (caspase-3, -6, -7, -8 and -9) | Mitochondrial dysfunction, collapse of mitochondrial membrane potential | Mitochondrial dysfunction, Production of ROS |
| Role of mitochondria | Release of cytochrome c, interaction with Bcl-2 protein family. Mitochondrial dysfunction | Failure of ATP production | AIF release |
| Complex formed    | Apoptosome | Pro-inflammatory response | Necroptosome |
| Inflammatory response | Anti- or proinflammatory response | Yes | Pro-inflammatory response |
| DAMP release      | | Pathological condition | Yes |
| Inhibitor         | Z-VAD fmk | Human condition: Physiological or pathological condition | Necrostatin-1 |
|                   | | | Pathological condition |

---

**Necroptosis and Inflammation**

Necroptosis is considered to be proinflammatory (Figure 2). Animal studies have revealed critical involvement for necroptosis in the pathogenesis of inflammatory diseases. Necroptosis is also demonstrated to lead to the release of damage-associated molecular patterns (DAMPs). DAMPs in the extracellular milieu trigger activation of the immune system and initiate inflammation. High-mobility group protein B1 (HMGB-1) is a typical DAMP molecule that initiates inflammation through toll-like receptors TLR-2 and TLR-4. Lau et al. demonstrated that RIPK1/RIPK3-mediated necroptosis regulates HMGB-1 release and HMGB-1 was reduced in RIPK3-/- renal graft after injury. Further in-depth studies need to be carried out to identify DAMPs specific for necroptosis, which would provide better interpretation of the role of necroptosis in tissue inflammation and provide new therapeutic targets for inflammatory diseases.
Hemorrhagic stroke: Although the role of necroptotic cell death after hemorrhagic stroke remains unexplored, the potential protective effect of Necrostatin-1 on such stroke has been investigated recently. In a mouse model of intracerebral hemorrhage, administration of Necrostatin-1 significantly reduced hematoma volume, neuronal cell death, reactive astrogliosis and neurovascular injury. The neurological outcomes were significantly improved after Necrostatin-1 treatment.

Amyotrophic lateral sclerosis: A study by Re et al. found that necroptosis is the key mechanism of neurodegeneration in both sporadic and familial types of amyotrophic lateral sclerosis (ALS). The sporadic and familial ALS astrocytes caused neuronal death by necroptosis in a RIPK1-dependent manner. Necrostatin-1 abrogated the mouse motor neuron loss in ALS.

Neurodegenerative disease: Necroptosis has been implicated in mediating neuronal excitotoxicity, which is associated with chronic neurodegeneration such as in Alzheimer’s and Parkinson’s diseases. Treatment with Necrostatin-1 protects against glutamate-induced excitotoxicity in hippocampal HT-22 cells. Furthermore, NMDA-induced excitotoxicity has been shown to be lowered in the rat cortical neurons through using Necrostatin-1. The molecule 24(S)-hydroxycholesterol (24S-OHC) was found to induce neuronal cell death via necroptosis in a neuroblastoma cell line. 24S-OHC is usually found as a cholesterol eliminator in brains, with increased levels in those patients with Alzheimer’s disease. Treatment of cells with Necrostatin-1 significantly suppressed cell death induced by 24S-OHC. This indicated that high levels of 24S-OHC might...
lead to necroptosis of neurons and contribute to the development of neurodegenerative diseases.\(^{46,47}\)

**Lung**

*Lung infection:* The cIAP may play a role in necroptosis within the lung during pulmonary infection.\(^{48}\) A study of necroptosis of macrophages demonstrated that with deficient cIAP-1, the mice had a greater *Chlamydophila pneumoniae* viral load, as well as a reduced number of macrophages.\(^{48}\) A deficiency in cIAP-1 would increase the risk of necroptosis due to increased formation of necrosomes. Flu infections caused necroptosis in the lung and bronchiolar epithelial tissue,\(^{48}\) mediated by RIPK1 and RIPK3, and inhibiting either or both of these proteins in mice has shown to be effective against lung infection.\(^{48}\) Recently, the role of necroptosis in listeria infection has been pointed out in detail.\(^{50}\)

**Remote lung injury:** Several reports have independently demonstrated that necroptosis is involved in remote lung injury. A recent study by Zang et al.\(^{51}\) examined rat lungs that were affected by acute kidney injury (AKI), and found that the lung cells with remote injury were undergoing both apoptosis and necroptosis. Furthermore, necroptosis was reported to be involved in remote lung injury after kidney graft IRI.\(^{52}\) In a rat renal allogeneic transplantation model, the expression of RIPK1 was enhanced in lung alveolar epithelial cells due to renal graft IRI, possibly due to enhanced local and systemic TNF-\(\alpha\).\(^{52}\) Blocking necroptosis through Necrostatin-1 conferred protection against remote lung injury after receiving ischemic renal allografts.\(^{52}\)

**Kidney**

*Cisplatin-induced kidney injury:* Necroptosis may be associated with the cisplatin toxicity-associated cell death and Necrostatin-1 has been shown to confer protection in cisplatin-treated human proximal tubular cells.\(^{57}\) In the mouse model of cisplatin-induced AKI, the deterioration of renal morphology was attenuated by Necrostatin-1.\(^{20}\) However, there are possible explanations, which include non-necroptotic functions of RIPK3 and off-target effects of Necrostatin-1 that might explain these findings which are not ruled out in detail. Renal tubular cells as such, when depleted from caspase-8 or FADD, are not sensitive to necroptosis in the cisplatin model.\(^{58}\)

**Renal ischemia–reperfusion injury:** Recent work has further implicated the relevance of necroptosis in AKI, especially renal IRI.\(^{59}\) It has been demonstrated that Necrostatin-1 protects from renal IRI, a finding that suggests that RIPK1-dependent necroptosis is present and has functional relevance in the pathophysiological course of ischemic kidney injury.\(^{58}\) Importantly, this study indicated the absence of an apoptotic contribution to deterioration of acute ischemic kidney failure. To rule out potential off-target effects of Necrostatin-1 and non-necroptotic functions of RIPK3, the potential inhibition of RIPK1-mediated necroptosis by Necrostatin-1s, a stable and highly RIPK1 kinase specific compound, remains to be investigated. Preliminary studies do not indicate a protective effect of Necrostatin-1s in this very same model. The investigation of RIPK1-kd (kinase dead) knock-in mice is currently expected to clarify this issue.

**Renal transplantation:** RIPK3-mediated necroptosis was demonstrated to be present in renal transplantation and has a major impact on kidney transplant survival.\(^{9}\) TNF-\(\alpha\) is expressed by infiltrating cells as well as kidney parenchymal cells during AKI, which enhanced RIPK3 expression.
Enhanced survival was observed in RIPK3\(^{-/-}\) kidney graft recipients. Studies to investigate Necrostatin-1s and Necrostatin-1 in a transplant setting are urgently awaited, but are delayed due to the short half-life of these small molecules. Importantly, for the transplant situation in particular, the side effects upon immunosuppression, especially viral control, should be carefully looked at.

**Heart**

*Cardiac ischemia and infarction:* It was reported\(^{60}\) that necrostatins inhibited myocardial cell death and reduced infarct size in the isolated perfused heart. In a study performed on guinea pig hearts, Koshinuma \textit{et al.}\(^{61}\) looked at the effect of inhibition of necroptotic and apoptotic cell death on protection against ischemia injury. The combined treatment of necroptosis inhibitor Necrostatin-1 and apoptosis inhibitor zVAD led to reduced infarct size and a greater treatment of necroptosis inhibitor Necrostatin-1 and apoptotic cell death. Necrostatin-1 had a much higher survival rate than those that did not receive the treatment.

**Liver**

*Alcoholic steatohepatitis:* The exact role of necroptosis in alcoholic steatohepatitis remains unclear. Roychowdhury \textit{et al.}\(^{69}\) reported that ethanol feeding activates both apoptotic as well as non-apoptotic cell death pathways. Ethanol induced RIPK3 expression that was independent of presence or absence of caspase inhibitor. Chronic ethanol-fed mice showed increased RIPK3 expression. Moreover, the liver biopsies of alcoholic liver disease patients also showed increased RIPK3 expression, which indicates the execution of necroptosis in human hepatic pathologies.\(^{69}\)

*Non-alcoholic steatohepatitis:* Gautheron \textit{et al.}\(^{70}\) used the methionine- and choline-deficient diet-induced model of steatohepatitis as a model of non-alcoholic steatohepatitis. RIPK3 mediates liver injury, inflammation, induction of hepatic progenitor cells/activated cholangiocytes and liver fibrosis.\(^{70}\) RIPK3 thus represents a promising target for future therapeutic strategies in patients with chronic metabolic liver disease. It has been suggested that MLKL increases mitochondrial ROS production and contributes to necroptosis during hepatic injury.\(^{71}\)

**Hepatotoxicity:** The role of Necrostatin-1 in protecting liver cell damage was recently investigated in the model of acetaminophen (APAP) induced hepatotoxicity.\(^{72,73}\) APAP induced the phosphorylation of RIPK1 and hence necrosome formation, and Necrostatin-1 was effective in blocking necrosome formation during APAP-induced hepatotoxicity via inhibition of RIPK1.\(^{72}\)

**Gastrointestinal tract**

*Crohn’s and ulcerative colitis:* RIPK1 was reported to regulate homeostasis and suppress inflammation in barrier tissues by inhibiting epithelial cell apoptosis and necroptosis.\(^{64}\) A study into children with inflammatory bowel disease showed that necroptosis might contribute to its progression by heightening intestinal inflammation.\(^{65}\) The study, by Pierdomenico \textit{et al.}, found a statistically significant result in children with two main bowel diseases – namely Crohn’s and ulcerative colitis. RIPK3 levels increased while caspase-8 decreased, which was a strong indicator for the presence of necroptosis. It is currently very suggestive to think of necroptosis as a cause of chronic inflammation in the gut, which might be dependent of RIPK3 and MLKL, potentially explaining the outstanding therapeutic success of infliximab, a drug that directly interferes with TNF-\(\alpha\).\(^{66,67}\)

**Terminal ileitis:** Gunther \textit{et al.}\(^{68}\) demonstrate necroptosis in the terminal ileum of patients with Crohn’s disease and suggest that regulating necroptosis in the intestinal epithelium is critical for the maintenance of intestinal immune homeostasis. Deletion of caspase-8 from intestinal epithelial cells led to spontaneous necroptosis, causing a Crohn’s-like phenotype in mice.\(^{68}\) Paneth cells appear to be critically involved in this process. Mice with a conditional deletion of caspase-8 in the intestinal epithelium treated with Necrostatin-1 had a much higher survival rate than those that did not receive the treatment.

**Remote liver injury:** Necroptosis was shown to be present in remote hepatic injury associated with ischemic acute kidney
Injury (AKI), TNFR and RIPK3 showed significantly high expression levels in immunoblot analyses, and positive hepatocytes of RIPK3 immunohistochemical staining were also evident in livers of rats with ischemic AKI.

Pancreas

Acute pancreatitis: RIPK3 deficiency was published by two initial reports in which the role of RIPK3 was highlighted for partial protection from cerulein-induced pancreatitis (CIP), suggesting that necroptizing pancreatitis may be attenuated by pharmacological interference of this pathway. However, other groups, who intended to reproduce this result, failed to do so and in fact observed stronger organ damage in the presence of Necrostatin-1. Recently, the same group also described that RIPK3-deficient mice are not protected from CIP. However, MLKL deficiency in a newly generated knockout mice was again shown to be responsible for the protection in the CIP model. In this regard, investigation of positivity for pMLKL in human pancreatitis sections would be very helpful to clarify the issue.

Hematopoietic system

Bone marrow failure: A study by Roderick et al. revealed that hematopoietic RIPK1 deficiency triggered both apoptotic and necroptotic death that was partially prevented by RIPK3 deficiency, but the role of TAK1 was not investigated here. Therefore, the inhibitory function of RIPK1 on RIPK3-mediated necroptosis regulated hematopoiesis and prevented inflammation in this model. Interestingly, RIPK3−/− bone-marrow-derived dendritic cells were highly defective in lipopolysaccharide (LPS)-induced expression of inflammatory cytokines. This dendritic cell-specific function of RIPK3 was critical for injury-induced inflammation and tissue repair. Rickard et al. demonstrated an essential physiological role for RIPK1 in immune homeostasis and emergency hematopoiesis. RIPK1 could inhibit RIPK3/MLKL necroptosis and MLKL deficiency prevented RIPK1−/− systemic inflammation. Specifically, bone marrow failure described by Roderick et al. and Rickard et al. reflects the loss of normal tissue homeostasis associated with the loss of RIPK1 protein and is different from the inappropriate activation of RIPK1 kinase activity. Similarly, the study by Moriwaki et al. demonstrated the kinase-independent role of RIPK3 in inflammation, which is again different from its kinase-dependent role in necroptosis.

Necroptosis as a Therapeutic Target

RIP-1 inhibitor. The central role of RIPK1 and RIPK3 in initiating necroptosis led to the assumption that inhibiting RIP is a good strategy against necroptosis. Necrostatins in animal disease models have been proven to be very useful experimental probes. However, RIPK1 kinase activity is not only limited to necroptosis but is also involved in ERK1/3 and NF-κB activation, therefore the biological effect after in vivo RIP inhibitor administration should be carefully interpreted. The kinase domain of RIPK1 appears to be of central importance in sepsis/LPS/TNF-mediated shock models. A range of chemical or biological compounds have been proposed or investigated as potential inhibitors of RIPK1 in organ injury.

Necrostatin-1: Recently, the 5-(1H-indol-3-ylmethyl)-2-thiohydantoin 1, termed Necrostatin-1 (or Nec-1), was reported to inhibit necroptosis induced by TNF-α. Necrostatin-1 has been considered an effective agent of necroptosis inhibition – possibly because the main cause of necroptosis is RIPK1 and RIPK3 forming the necrosome. However, this treatment so far has only been used in the preclinical stage, so further studies are needed for its development as a drug for clinical use. The precise function of the kinase-inhibitor Necrostatin-1 is well established that this molecule is an allosteric inhibitor of RIPK1, stabilizing a specific inactive conformation of the kinase domain. It inhibits in vitro necroptosis and the in vivo effects seen with this compound are strong, and have been reported by several groups. RIPK1/3 activation is induced by homotypic RHIM domain interactions with upstream activators, such as TRIF. Loss of RIPK1 leads to the new parameters of direct RIPK3 activation by the same adaptors, which is clearly detrimental to the organism. However, this also indicates that the conclusion that necroptosis is RIPK1-independent has to be considered very carefully as regulation of RIPK3 in the presence of RIPK1 and its absence is not equivalent. Instead, it is clear that Necrostatin-1 lacks activity in the absence of RIPK1, indicating its specific mode of action. Rather, these data indicate that RIPK1 has an important dual role in controlling cell death: both as an attenuator of RIPK3 activation under normal circumstances and as an inducer when necroptosis is activated under pathologic conditions. Thus, activation of necroptosis in RIPK1−/− cells is not always a clear reflection of the lack of RIPK1 role under normal circumstances. In addition, RIPK1-kd knock-in mice are viable whereas whole-body RIPK1-ko are lethal at day 10.5 in utero. Conversely, unlike Necrostatin-1 derivatives such as Necrostatin-1s, Necrostatin-1 is a reactive and to some extent non-specific inhibitor, which may explain some discrepancies in the activities of the two molecules.

Necrostatin-1 derivatives: The new Necrostatin-1 analog, Necrostatin-1 stable (Necrostatin-1s) (7-CI-O-Nec-1), was found to be 41 000-fold more selective for RIPK1 than for any other kinase. Moreover, a small group substitution at the seventh position of the indole of Necrostatin-1 and a change from thiohydantoin to hydantoin significantly enhanced its inhibitory activity. Necrostatin-1s was demonstrated to be very effective in reducing brain injuries.

Other RIP-1 inhibitors: Harris et al. discovered some inhibitors for RIPK1 from three different molecule families. One of these families, furo[2,3-d]pyrimidines, has been shown to protect rats from hypothermia induced by TNF-α. Weng et al. demonstrated that RIPK1 inhibitor GSK963, but not inactive enantiomer GSK962, blocks Yersinia pestis-induced cell death and caspase-8 activity. Caspase-8 conditional KO macrophages are protected from...
Y. pestis-induced death in the presence of RIPK1 (GSK’963) or RIPK3 (GSK’872) kinase inhibitors.93

RIPK3 inhibitor. The ability of RIPK3 deficiency to prevent disease has heightened interest in the therapeutic potential of small-molecule inhibitors that target RIPK3 kinase activity. Mandal et al.94 demonstrated that three selective small-molecule compounds (GSK’840, GSK’843 and GSK’872) to inhibit RIPK3-dependent necroptosis. These compounds interact with RIPK3 to activate caspase-8 (Casp8). RIPK3-inhibiting compounds blocked TNF-induced necroptosis in a concentration-dependent manner. In addition, RIPK3 inhibitors prevent death from a broader range of stimuli than RIPK1 concentration-dependent manner. In addition, RIPK3 inhibition compounds blocked TNF-induced necroptosis in a concentration-dependent manner. In addition, RIPK3 inhibitors prevent death from a broader range of stimuli than RIPK1 inhibitors. Li et al.95 reported that RIPK3 activation following the induction of necroptosis required the activity of an HSP90 and a CDC37 cochaperone complex. Chemical inhibitors of HSP90 efficiently block necroptosis by preventing RIPK3 activation.

Potential cytotoxicity of RIPK3 inhibition compounds was recently observed and revealed by Mandal et al.94 Transmission electron microscopy confirmed apoptotic cell morphology associated with RIPK3 cytotoxicity, indicating that RIPK3 inhibition compounds could induce apoptotic cell death.

Inhibitor of downstream signalling components. The downstream signalling cascade of RIPK1 may provide a significant array of novel candidate of therapeutic targets. This area certainly warrants further research.

MLKL inhibitor: The RIP downstream effector, MLKL, has been identified as another target of antinecroptosis therapy.96 A new compound named necrosulfonamide ((E)-N-(4-(N-(3-methoxyprazin-2-yl) sulfonyl)phenyl)-3-(5-nitrophenyl-2-yl) acrylamide), referred to as NSA, can effectively block TNF-induced necroptosis in human cells through interacting with MLKL.4 NSA could become a new drug for clinical applications in treating necroptosis related human disease.

Conclusion

Based on effects seen in RIPK3-deficient mice, and on preclinical investigation of Necrostatin-1, a pathophysiological role of necroptosis in numerous diseases may be concluded.97,98 Although the molecular mechanisms of necroptosis have not been fully explored, it is clearly possible that this process is involved in promoting organ injury. Thus, further understanding of the underlying mechanisms of necroptosis and its inhibition has important implications for organ protection and should have a significant impact on the development of therapeutic intervention of related human diseases.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. This work was supported by the British Medical Research Council, The Developmental Pathway Funding Scheme program (project grant G802392), BJA/RCoA Research Fellowship grant. Work in the Linkermann-lab is supported by the German Research Foundation, EXC306, Inflammation at Interfaces.
Necroptosis in solid organ injury

H Zhao et al

30. Roderick JE, Hermance N, Zeil M, Simmons MJ, Polakrastis A, Pasparakis M et al. Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis. *Proc Natl Acad Sci USA* 2014; 111: 14346–14411.

31. Davidson P, Kasey CM, Martin SJ. Inflammatory outcomes of apoptosis, necrosis and necroptosis. *Biochim Biophys Acta* 2014; 1845: 1163–1171.

32. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517: 311–320.

33. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331–342.

34. Kaczmarek A, Vandenabeele P, Krzywil NV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013; 38: 209–223.

35. Triantou VR, Goncalves PF, Dalboni MA, Batista MC, Durao M de S Jr., Monte JC. Programmed necrosis as a prominent mechanism of cell death following neonatal brain injury. *Neuro Res Int* 2012; 2012: 257563.

36. Northjngt RJ, Chavez-Valez R, Graham EM, Razdan S, Gauda BM, Martin LJ. Necrostatin decreases oxidative damage, inflammation, and injury after neonatal HI. *J Cereb Blood Flow Metab* 2011; 31: 178–189.

37. Selman W, Oldfield E, Vila P, Vila J, Muzhinina N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. *Nat Chem Biol* 2005; 1: 112–119.

38. Koolman E, Nijboer CH, van Velthoven CT, Kavelaars A, Kesecioglu J, Heijnen CJ. The role of mitophagy in cellular necrosis. *Nat Cell Biol* 2014; 16: 495817.

39. Re DB, Le Verche V, Yu C, Amrosso MW, Politi KA, Phari S et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. *Neuron* 2014; 81: 1001–1008.

40. Xu X, Chua CC, Kong J, Kostrzewa RM, Kumaraguru U, Hamdy RC et al. Programmed necrosis in acute kidney injury. *Nephrol Dial Transplant* 2012; 27: 3412–3419.

41. Chavez-Valez R, Martin LJ, Northington RJ. Programmed necrosis: a prominent mechanism of cell death following neonatal brain injury. *Neuro Res Int* 2012; 2012: 257563.

42. King MD, Whitaker-Lea WA, Campbell JM, Alleynie CH, Dhondapani KM. Necrostatin-1 reduces neurogenic injury after intracerebral hemorrhage. *Int J Cell Biol* 2014; 2014: 319724.

43. Davidovich P, Kearney CJ, Martin SJ. Inflammatory outcomes of apoptosis, necrosis and necroptosis. *J Neurochem* 2014; 128: 223–240.

44. Koshinuma S, Miyamae M, Kaneda K, Kofani J, Figueredo VM. Combination of necroptosis and caspase-8 inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. *J Anesth* 2014; 38: 235–241.

45. Oerlemans MI, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans PA et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. *Basic Res Cardiol* 2012; 107: 270.

46. Liu J, Li H, Yang M, Ren J, Huang Z, Han F et al. A role of RIP3-mediated macrophage necroptosis in atherosclerosis development. *Cell Rep* 2013; 3: 200–210.

47. Dannappel M, Vlantis K, Kumari S, Polakrastis A, Kim C, Wachsmuth SL et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014; 513: 90–94.

48. Koushina S, Miyamae M, Kaneda K, Kotani J, Figueredo VM. Combination of necroptosis and caspase-8 inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. *J Anesth* 2014; 38: 235–241.

49. Baixauli J, Li H, Xiao J, Bell GI, Brasseur AM et al. Liver-resident macrophage necroptosis contributes to the pathogenesis of COPD. *Cell Rep* 2013; 3: 200–210.

50. Bleriot C, Dupuis T, Jouvion G, Eberl G, Disson O, Lecuit M. Liver-resident macrophage necroptosis contributes to the pathogenesis of COPD. *Cell Rep* 2013; 3: 200–210.

51. Zhao H, Ning J, Lemaire A, Koumpa FS, Sun JJ, Fung A et al. Liver-resident macrophage necroptosis contributes to the pathogenesis of COPD. *Cell Rep* 2013; 3: 200–210.

52. Rodrigue-Gervais IG, Labbe K, Dagenais M, Dupaul-Chicoine J, Champagne C, Morizot A et al. Maintenance inflammasome for COPD’s disease: the ACCENT I randomised trial. *Lancet* 2002; 359: 1541–1549.

53. Gurur G, Martini E, Wittkopp LF, Amani K, Weigmann B, Neumann H et al. Caspase-8 regulates RIPK1-induced epithelial necroptosis and terminal ileitis. *Nature 2011; 477: 335–339.

54. Reiling G, Nuss B, Feagan BG, Lichtenstein MR, Meyer LF, Schreiber S, Colombel JF et al. Maintenance inflammasome for COPD’s disease: the ACCENT I randomised trial. *Lancet* 2002; 359: 1541–1549.

55. Luedde T; Kaplowlitz N, Schwaabc RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. *Gastroenterology* 2014; 147: 769–781 e746.

56. Takekoto K, Hatako E, Iwashiso K, Takei M, Nomura N, Ohnmae S et al. Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatocytocn apoptosis in aeticaminophen induced acute liver failure. *FEBS Open Bio* 2014; 4: 777–787.

57. Fu yu, Liu Y, Wang K, Wang W, Wang J, Zhang C et al. Necroptosis contributes to the NMDA-induced excitotoxicity in rat’s cultured cortical neurons. *Proc Natl Acad Sci USA* 2007; 104: 13640–13645.

58. Yamanaka K, Urano Y, Noguchi N. 24(S)-hydroxycholesterol induces neuronal cell death through necroptosis, a form of programmed necrosis. *J Neurochem* 2012; 123: 2132–2141.

59. Triantou VR, Goncalves PF, Dalboni MA, Batista MC, Durao M de S Jr., Monte JC. Programmed necrosis as a prominent mechanism of cell death following neonatal brain injury. *Neuro Res Int* 2012; 2012: 257563.

60. Linkermann A, Skoua R, Himmelus N, Muyal SR, Dewtz C, Dezen F et al. Synchronized renal tubular cell death involves ferroptosis. *Proc Natl Acad Sci USA* 2014; 111: 12356–12361.

61. Linkermann A, Chen G, Dong G, Kurzendorf U, Krautwald S, Dong Z. Regulated cell death in AKI. *J Am Soc Nephrol* 2014; 25: 2689–2701.

62. Smith CC, Davidson SM, Lim SY, Simplek JC, Hothersall JS, Yellon DM. Necrostatin-1: a potentially novel cardoprotective agent? *Cardiovasc Drugs Ther* 2007; 21: 227–233.

63. Koushina S, Miyamae M, Kaneda K, Kotani J, Figueredo VM. Combination of necroptosis and caspase-8 inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. *J Anesth* 2014; 38: 235–241.

64. Oerlemans MI, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans PA et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. *Basic Res Cardiol* 2012; 107: 270.

65. Liu J, Li H, Yang M, Ren J, Huang Z, Han F et al. A role of RIP3-mediated macrophage necroptosis in atherosclerosis development. *Cell Rep* 2013; 3: 200–210.

66. Dannappel M, Vlantis K, Kumari S, Polakrastis A, Kim C, Wachsmuth SL et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014; 513: 90–94.

67. Koushina S, Miyamae M, Kaneda K, Kotani J, Figueredo VM. Combination of necroptosis and caspase-8 inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. *J Anesth* 2014; 38: 235–241.
Necroptosis in solid organ injury

H Zhao et al.